Cancer Research and Treatment

Original Articles

General

Establishment of Patient-Derived Organoids Using Ascitic or Pleural Fluid from Cancer Patients: Wonyoung Choi, Yun-Hee Kim, Sang Myung Woo, Yebeen Yu, Mi Rim Lee, Woo Jin Lee, Jung Won Chun, Sung Hoon Sim, Heejung Chae, Hyoeun Shim, Keun Seok Lee, Sun-Young Kong; Cancer Res Treat. 2023;55(4):1077-1086. Published online June 12, 2023; DOI: https://doi.org/10.4143/crt.2022.1630

Abstract PDF Supplementary Material PubReader ePub

Purpose
Patient-derived tumor cells can be a powerful resource for studying pathophysiological mechanisms and developing robust strategies for precision medicine. However, establishing organoids from patient-derived cells is challenging because of limited access to tissue specimens. Therefore, we aimed to establish organoids from malignant ascites and pleural effusions.
Materials and Methods
Ascitic or pleural fluid from pancreatic, gastric, and breast cancer patients was collected and concentrated to culture tumor cells ex vivo. Organoids were considered to be successfully cultured when maintained for five or more passages. Immunohistochemical staining was performed to compare the molecular features, and drug sensitivity was assayed to analyze the clinical responses of original patients.
Results
We collected 70 fluid samples from 58 patients (pancreatic cancer, n=39; gastric cancer, n=21; and breast cancer, n=10). The overall success rate was 40%; however, it differed with types of malignancy, with pancreatic, gastric, and breast cancers showing 48.7%, 33.3%, and 20%, respectively. Cytopathological results significantly differed between successful and failed cases (p=0.014). Immunohistochemical staining of breast cancer organoids showed molecular features identical to those of tumor tissues. In drug sensitivity assays, pancreatic cancer organoids recapitulated the clinical responses of the original patients.
Conclusion
Tumor organoids established from malignant ascites or pleural effusion of pancreatic, gastric, and breast cancers reflect the molecular characteristics and drug sensitivity profiles. Our organoid platform could be used as a testbed for patients with pleural and peritoneal metastases to guide precision oncology and drug discovery.

Citations

Citations to this article as recorded by

PRMT1 promotes pancreatic cancer development and resistance to chemotherapy
Bomin Ku, David Eisenbarth, Seonguk Baek, Tae-Keun Jeong, Ju-Gyeong Kang, Daehee Hwang, Myung-Giun Noh, Chan Choi, Sungwoo Choi, Taejun Seol, Hail Kim, Yun-Hee Kim, Sang Myung Woo, Sun-Young Kong, Dae-Sik Lim
Cell Reports Medicine.2024; 5(3): 101461. CrossRef
Establishment and Advancement of Pancreatic Organoids
Dong Hyeon Lee
Keimyung Medical Journal.2024; 43(1): 3. CrossRef
Organoid as a promising tool for primary liver cancer research: a comprehensive review
Xuekai Hu, Jiayun Wei, Pinyan Liu, Qiuxia Zheng, Yue Zhang, Qichen Zhang, Jia Yao, Jingman Ni
Cell & Bioscience.2024;[Epub] CrossRef
The use of organoids in creating immune microenvironments and treating gynecological tumors
Ling-Feng Zhou, Hui-Yan Liao, Yang Han, Yang Zhao
Journal of Translational Medicine.2024;[Epub] CrossRef
Organoid: Bridging the gap between basic research and clinical practice
Guihu Weng, Jinxin Tao, Yueze Liu, Jiangdong Qiu, Dan Su, Ruobing Wang, Wenhao Luo, Taiping Zhang
Cancer Letters.2023; 572: 216353. CrossRef

4,864 View
480 Download
4 Web of Science
5 Crossref

EGFR Mutation Status in Lung Adenocarcinoma-Associated Malignant Pleural Effusion and Efficacy of EGFR Tyrosine Kinase Inhibitors: Jiyoul Yang, Ok-Jun Lee, Seung-Myoung Son, Chang Gok Woo, Yusook Jeong, Yaewon Yang, Jihyun Kwon, Ki Hyeong Lee, Hye Sook Han; Cancer Res Treat. 2018;50(3):908-916. Published online September 19, 2017; DOI: https://doi.org/10.4143/crt.2017.378

Abstract PDF PubReader ePub

Purpose
Malignant pleural effusions (MPEs) are often observed in lung cancer, particularly adenocarcinoma. The aim of this study was to investigate epidermal growth factor receptor (EGFR) mutation status in lung adenocarcinoma-associated MPEs (LA-MPEs) and its correlation with efficacy of EGFR tyrosine kinase inhibitor (TKI) therapy.
Materials and Methods
Samples comprised 40 cell blocks of pathologically-confirmed LA-MPEs collected before the start of EGFR TKI therapy. EGFR mutation status was re-evaluated by peptide nucleic acid clamping and the clinical outcomes of EGFR TKI‒treated patients were analyzed retrospectively.
Results
EGFR mutations were detected in 72.5% of LA-MPE cell blocks (29/40). The median progression-free survival for patients with EGFR mutations in LA-MPEs was better than that for patients with wild-type EGFR (7.33 months vs. 2.07 months; hazard ratio, 0.486; 95% confidence interval, 0.206 to 1.144; p=0.032). The objective response rate (ORR) of 26 patients with EGFR mutations in LA-MPEs among the 36 patients with measurable lesions was 80.8%, while the ORR of the 10 patients with wild-type EGFR in LA-MPEs was 10% (p < 0.001). Among the 26 patients with EGFR mutations in LA-MPEs, the ORR of target lesions and LA-MPEs were 88.5% and 61.5%, respectively (p=0.026).
Conclusion
EGFR mutation status in cell blocks of LA-MPEs confirmed by pathologic diagnosis is highly predictive of EGFR TKI efficacy. For patients with EGFR mutations in LA-MPEs, the response to EGFR TKIs seems to be worse for pleural effusions than for solid tumors.

Citations

Citations to this article as recorded by

Cancer‐associated fibroblast‐derived colony‐stimulating factor 2 confers acquired osimertinib resistance in lung adenocarcinoma via promoting ribosome biosynthesis
Yutang Huang, Xiaoqing Wang, Chunjie Wen, Jingchan Wang, Honghao Zhou, Lanxiang Wu
MedComm.2024;[Epub] CrossRef
Effect of chemotherapy, immunotherapy, and targeted therapies on removal of indwelling pleural catheters in non-small cell lung cancer patients with malignant pleural effusions
Melissa Wang, Kaitlin Sparrow, Chrystal Chan, Ashley Gillson, Daniel Stollery, Pen Li
Respiratory Medicine.2023; 206: 107093. CrossRef
Malignant pleural effusion diagnosis and therapy
Liangliang Yang, Yue Wang
Open Life Sciences.2023;[Epub] CrossRef
Failure pattern and radiotherapy exploration in malignant pleural effusion non-small cell lung cancer treated with targeted therapy
Qingsong Li, Cheng Hu, Shengfa Su, Zhu Ma, Yichao Geng, Yinxiang Hu, Huiqin Li, Bing Lu
Frontiers in Oncology.2023;[Epub] CrossRef
Impact of thoracic tumor radiotherapy on survival in non‐small‐cell lung cancer with malignant pleural effusion treated with targeted therapy: Propensity score matching study
Qingsong Li, Cheng Hu, Shengfa Su, Zhu Ma, Yichao Geng, Yinxiang Hu, Haijie Jin, Huiqin Li, Bing Lu
Cancer Medicine.2023; 12(14): 14949. CrossRef
EGFR Mutation is a Prognostic Factor in Lung Cancer Patients with Pleural Dissemination Detected During or After Surgery
Toshiya Fujiwara, Kazuhiko Shien, Motoki Matsuura, Junichi Soh, Hiromasa Yamamoto, Soshi Takao, Yuho Maki, Tsuyoshi Ueno, Ryujiro Sugimoto, Ken Suzawa, Mikio Okazaki, Hiroyuki Tao, Makio Hayama, Masafumi Kataoka, Yoshifumi Sano, Hidetoshi Inokawa, Motohir
Annals of Surgical Oncology.2023; 30(11): 6697. CrossRef
Efficacy of hyperthermic intrathoracic chemotherapy for initially diagnosed lung cancer with symptomatic malignant pleural effusion
Zihui Li, Jie Deng, Fei Yan, Li Liu, Yanling Ma, Jianhai Sun
Scientific Reports.2023;[Epub] CrossRef
Establishment of prognostic nomograms for predicting the progression free survival of EGFR‐sensitizing mutation, advanced lung cancer patients treated with EGFR‐TKIs
Xinyang Du, Hua Bai, Zhijie Wang, Jianchun Daun, Zheng Liu, Jiachen Xu, Geyun Chang, Yixiang Zhu, Jie Wang
Thoracic Cancer.2022; 13(9): 1289. CrossRef
Clinical features and prognosis according to genomic mutations in primary and metastatic lesions of non‐small‐cell lung cancer
Wei Zhang, Wenjuan Han, Bo Yu, Xin Zhao, Gaojun Lu, Wendy Wu, Yi Zhang
Thoracic Cancer.2022; 13(11): 1642. CrossRef
Management of Malignant Pleural Effusion: Where Are We Now?
Julien Guinde, Hervé Dutau, Philippe Astoul
Seminars in Respiratory and Critical Care Medicine.2022; 43(04): 559. CrossRef
Non-Small Cell Lung Cancer with Malignant Pleural Effusion May Require Primary Tumor Radiotherapy in Addition to Drug Treatment
Qingsong Li, Cheng Hu, Shengfa Su, Zhu Ma, Yichao Geng, Yinxiang Hu, Huiqin Li, Bing Lu
Cancer Management and Research.2022; Volume 14: 3347. CrossRef
The impact of smoking status on the progression‐free survival of non‐small cell lung cancer patients receiving molecularly target therapy or immunotherapy versus chemotherapy: A meta‐analysis
Xinyi Li, Cong Huang, Xiaohui Xie, Ziyang Wu, Xia Tian, Yibo Wu, Xin Du, Luwen Shi
Journal of Clinical Pharmacy and Therapeutics.2021; 46(2): 256. CrossRef
Risk Factors for and Time to Recurrence of Symptomatic Malignant Pleural Effusion in Patients With Metastatic Non-Small Cell Lung Cancer with EGFR or ALK Mutations
Audra J. Schwalk, David E. Ost, Sahara N. Saltijeral, Henriette De La Garza, Roberto F. Casal, Carlos A. Jimenez, Georgie A. Eapen, Jeff Lewis, Waree Rinsurongkawong, Vadeerat Rinsurongkawong, Jack Lee, Yasir Elamin, Jianjun Zhang, Jack A. Roth, Stephen S
Chest.2021; 159(3): 1256. CrossRef
Advances in pleural infection and malignancy
Eihab O. Bedawi, Julien Guinde, Najiib M. Rahman, Philippe Astoul
European Respiratory Review.2021; 30(159): 200002. CrossRef
Diving into the Pleural Fluid: Liquid Biopsy for Metastatic Malignant Pleural Effusions
Maria Alba Sorolla, Anabel Sorolla, Eva Parisi, Antonieta Salud, José M. Porcel
Cancers.2021; 13(11): 2798. CrossRef
Clinical Characteristics and Therapeutic Outcomes of Metastatic Peritoneal Carcinomatosis in Non-Small-Cell Lung Cancer
Tetsuo Tani, Ichiro Nakachi, Shinnosuke Ikemura, Shigenari Nukaga, Keiko Ohgino, Aoi Kuroda, Hideki Terai, Keita Masuzawa, Taro Shinozaki, Kota Ishioka, Yohei Funatsu, Hidefumi Koh, Koichi Fukunaga, Kenzo Soejima
Cancer Management and Research.2021; Volume 13: 7497. CrossRef
LENT Score: Predicting the Survival of Malignant Pleural Effusion – A Prospective Study of Three Years
Sara Raimundo, Ana Isabel Loureiro, Fortunato Vieira, Ana Fernandes
Archivos de Bronconeumología.2020; 56(7): 465. CrossRef
Current applications of molecular testing on body cavity fluids
Daniel Pinto, Fernando Schmitt
Diagnostic Cytopathology.2020; 48(9): 840. CrossRef
Gene Alterations in Paired Supernatants and Precipitates from Malignant Pleural Effusions of Non-Squamous Non-Small Cell Lung Cancer
Jianqiang Li, Xingliang Li, Wenxian Wang, Yang Shao, Yiping Zhang, Zhengbo Song
Translational Oncology.2020; 13(8): 100784. CrossRef
Progression of malignant pleural effusion during the early stage of gefitinib treatment in advanced EGFR-mutant lung adenocarcinoma involving complex driver gene mutations
Ning Liu, Min Yu, Tao Yin, Yong Jiang, Xuelian Liao, Jie Tang, Yanying Li, Diyuan Qin, Dan Li, Yongsheng Wang
Signal Transduction and Targeted Therapy.2020;[Epub] CrossRef
LENT Score: Predicting the Survival of Malignant Pleural Effusion – A Prospective Study of Three Years
Sara Raimundo, Ana Isabel Loureiro, Fortunato Vieira, Ana Fernandes
Archivos de Bronconeumología (English Edition).2020; 56(7): 465. CrossRef
Recent Developments in the Management of Malignant Pleural Effusions: a Narrative Review
Clifford E. Coile, Jessie G. Harvey, Michal Senitko
Current Pulmonology Reports.2020; 9(4): 164. CrossRef
Detecting EGFR mutations and ALK/ROS1 rearrangements in non‐small cell lung cancer using malignant pleural effusion samples
Yi Yao, Min Peng, Qinglin Shen, Qinyong Hu, Hongyun Gong, Qingqing Li, Zhongliang Zheng, Bin Xu, Yingge Li, Yi Dong
Thoracic Cancer.2019; 10(2): 193. CrossRef
Making cold malignant pleural effusions hot: driving novel immunotherapies
Pranav Murthy, Chigozirim N. Ekeke, Kira L. Russell, Samuel C. Butler, Yue Wang, James D. Luketich, Adam C. Soloff, Rajeev Dhupar, Michael T. Lotze
OncoImmunology.2019; 8(4): e1554969. CrossRef
Novel insights into the systemic treatment of lung cancer malignant pleural effusion
Claire Tissot, Pierre Gay, Clément Brun, Marios E. Froudarakis
The Clinical Respiratory Journal.2019; 13(3): 131. CrossRef
Proceedings of the American Society of Cytopathology companion session at the 2019 United States and Canadian Academy of Pathology Annual meeting, part 2: effusion cytology with focus on theranostics and diagnosis of malignant mesothelioma
Momin T. Siddiqui, Fernando Schmitt, Andrew Churg
Journal of the American Society of Cytopathology.2019; 8(6): 352. CrossRef

10,014 View
279 Download
35 Web of Science
26 Crossref

Diagnostic Value of Circulating Extracellular miR-134, miR-185, and miR-22 Levels in Lung Adenocarcinoma-Associated Malignant Pleural Effusion: Yoon Mi Shin, Jieun Yun, Ok-Jun Lee, Hye-Suk Han, Sung-Nam Lim, Jin Young An, Ki Hyeong Lee, Ki Man Lee, Kang Hyeon Choe; Cancer Res Treat. 2014;46(2):178-185. Published online April 15, 2014; DOI: https://doi.org/10.4143/crt.2014.46.2.178

Abstract PDF PubReader ePub

Purpose

The accurate and timely diagnosis of malignant pleural effusion (MPE) in lung cancer patients is important because MPE has a poor prognosis and is classified as stage IV disease. Molecular biomarkers for pleural effusion, such as circulating extracellular microRNAs (miRNAs) isolated from pleural fluid, may help in the diagnosis of MPE. The present study examined whether miRNAs that are deregulated in lung cancer (miR-134, miR-185, and miR-22) can serve as diagnostic markers for lung adenocarcinoma-associated MPE (LA-MPE).

Materials and Methods

Real-time reverse transcription quantitative polymerase chain reaction was used to measure the expression of the three miRNAs in samples from 87 patients with pleural effusion comprising 45 LA-MPEs and 42 benign pleural effusions (BPEs). The area under the receiver operating characteristic curve (AUC) was then used to evaluate the diagnostic performance of each of the three miRNAs and compare it with that of the common tumor marker, carcinoembryonic antigen (CEA).

Results

The expression of all three miRNAs was significantly lower in LA-MPE than in BPE (p <0.001). The AUCs for miR-134, miR-185, miR-22, and CEA were 0.721, 0.882, 0.832, and 0.898, respectively. Combining CEA with the three miRNAs increased the diagnostic performance, yielding an AUC of 0.942 (95% confidence interval, 0.864 to 0.982), with a sensitivity of 91.9% and a specificity of 92.5%.

Conclusion

The present study suggests that the expression levels of circulating extracellular miR-134, miR-185, and miR-22 in patients with pleural effusion may have diagnostic value when differentiating between LA-MPE and BPE.

Citations

Citations to this article as recorded by

Key methodological challenges in detecting circulating miRNAs in different biofluids
Chitra Mestry, Tester F Ashavaid, Swarup AV Shah
Annals of Clinical Biochemistry: International Journal of Laboratory Medicine.2023; 60(1): 14. CrossRef
MiRNAs in Lung Adenocarcinoma: Role, Diagnosis, Prognosis, and Therapy
Yongan Song, Leonardo Kelava, István Kiss
International Journal of Molecular Sciences.2023; 24(17): 13302. CrossRef
High Diagnostic and Prognostic Value of miRNAs Compared with the Carcinoembryonic Antigen As A Traditional Tumor Marker
Neda Yaghoubi , Farnaz Zahedi Avval , Majid Khazaei, Amirhossein Sahebkar , Seyed Hamid Aghaee-Bakhtiari
Anti-Cancer Agents in Medicinal Chemistry.2022; 22(2): 206. CrossRef
Diagnostic utility of pleural cell-free nucleic acids in undiagnosed pleural effusions
Wen Zhao, Xi-Shan Cao, Yu-Ling Han, Xu-Hui Wen, Wen-Qi Zheng, Zhi-De Hu
Clinical Chemistry and Laboratory Medicine (CCLM).2022; 60(10): 1518. CrossRef
Construction and analysis of expression profile of exosomal lncRNAs in pleural effusion in lung adenocarcinoma
Xiaolu Huang, Huixin Zhou, Xiang Yang, Wenjing Shi, Lijuan Hu, Junjun Wang, Fan Zhang, Fanggui Shao, Meijuan Zhang, Feng Jiang, Yumin Wang
Journal of Clinical Laboratory Analysis.2022;[Epub] CrossRef
Molecular testing on serous effusions
Ben Davidson
Diagnostic Cytopathology.2021; 49(5): 640. CrossRef
Diving into the Pleural Fluid: Liquid Biopsy for Metastatic Malignant Pleural Effusions
Maria Alba Sorolla, Anabel Sorolla, Eva Parisi, Antonieta Salud, José M. Porcel
Cancers.2021; 13(11): 2798. CrossRef
Four plasma miRNAs act as biomarkers for diagnosis and prognosis of non‑small cell lung cancer
He-Guo Jiang, Chun-Hua Dai, Ya-Ping Xu, Qian Jiang, Xian-Bin Xia, Yang Shu, Jian Li
Oncology Letters.2021;[Epub] CrossRef
Molecular testing on serous effusion: An update
Saumya Sahu, Parikshaa Gupta, Pranab Dey
Cytojournal.2021; 18: 35. CrossRef
Non-coding RNA and lung cancer progression
Afeez Adekunle Ishola, Anita Silas La’ah, Hung Dinh Le, Viet Quoc Nguyen, Yi-Ping Yang, Shih-Jie Chou, Hsiao-Yun Tai, Chian-Shiu Chien, Mong-Lien Wang
Journal of the Chinese Medical Association.2020; 83(1): 8. CrossRef
Role of microRNAs as Clinical Cancer Biomarkers for Ovarian Cancer: A Short Overview
Cristina Elena Staicu, Dragoș-Valentin Predescu, Călin Mircea Rusu, Beatrice Mihaela Radu, Dragos Cretoiu, Nicolae Suciu, Sanda Maria Crețoiu, Silviu-Cristian Voinea
Cells.2020; 9(1): 169. CrossRef
microRNA exchange via extracellular vesicles in cancer
Luyen Tien Vu, Jinhua Gong, Thach Tuan Pham, Yeokyeong Kim, Minh T. N. Le
Cell Proliferation.2020;[Epub] CrossRef
MicroRNA Signatures in Malignant Pleural Mesothelioma Effusions
Kimberly A. Birnie, Cecilia M. Prêle, Arthur W. (Bill) Musk, Nicholas de Klerk, Y. C. Gary Lee, Deirdre Fitzgerald, Richard J. N. Allcock, Philip J. Thompson, Jenette Creaney, Bahareh Badrian, Steven E. Mutsaers
Disease Markers.2019; 2019: 1. CrossRef
Combination of DNA ploidy analysis and miR-21 or miR-24 in screening malignant pleural effusion
Chongmei Liu, Liuyan Huang, Xuechun Zhang, Juan Yang
Interactive CardioVascular and Thoracic Surgery.2018; 26(3): 376. CrossRef
Microarray expression profile and analysis of circular RNA regulatory network in malignant pleural effusion
Yakun Wen, Yong Wang, Zhenchuan Xing, Zongjian Liu, Ziliang Hou
Cell Cycle.2018; 17(24): 2819. CrossRef
Diagnostic value of tumor markers for lung adenocarcinoma-associated malignant pleural effusion: a validation study and meta-analysis
Mei Feng, Jing Zhu, Liqun Liang, Ni Zeng, Yanqiu Wu, Chun Wan, Yongchun Shen, Fuqiang Wen
International Journal of Clinical Oncology.2017; 22(2): 283. CrossRef
miR-134: A Human Cancer Suppressor?
Jing-Yu Pan, Feng Zhang, Cheng-Cao Sun, Shu-Jun Li, Guang Li, Feng-Yun Gong, Tao Bo, Jing He, Rui-Xi Hua, Wei-Dong Hu, Zhan-Peng Yuan, Xin Wang, Qi-Qiang He, De-Jia Li
Molecular Therapy - Nucleic Acids.2017; 6: 140. CrossRef
Molecular mechanisms and clinical applications of miR-22 in regulating malignant progression in human cancer (Review)
Jingyu Wang, Yuan Li, Meiman Ding, Honghe Zhang, Xiaoming Xu, Jinlong Tang
International Journal of Oncology.2017; 50(2): 345. CrossRef
MicroRNA-134 modulates glioma cell U251 proliferation and invasion by targeting KRAS and suppressing the ERK pathway
Yuguang Zhao, Dong Pang, Cui Wang, Shijiang Zhong, Shuang Wang
Tumor Biology.2016; 37(8): 11485. CrossRef
MicroRNA profiling of cisplatin-resistant oral squamous cell carcinoma cell lines enriched with cancer-stem-cell-like and epithelial-mesenchymal transition-type features
Ruma Dey Ghosh, Sangeeta Ghuwalewala, Pijush Das, Sapan Mandloi, Sk Kayum Alam, Jayanta Chakraborty, Sajal Sarkar, Saikat Chakrabarti, Chinmoy Kumar Panda, Susanta Roychoudhury
Scientific Reports.2016;[Epub] CrossRef
Cell‐free microRNAs in blood and other body fluids, as cancer biomarkers
Blanca Ortiz‐Quintero
Cell Proliferation.2016; 49(3): 281. CrossRef
Clinical relevance of circulating cell-free microRNAs in ovarian cancer
Koji Nakamura, Kenjiro Sawada, Akihiko Yoshimura, Yasuto Kinose, Erika Nakatsuka, Tadashi Kimura
Molecular Cancer.2016;[Epub] CrossRef
MicroRNA-432 functions as a tumor suppressor gene through targeting E2F3 and AXL in lung adenocarcinoma
Ling Chen, Guangming Kong, Chuantao Zhang, Hongyan Dong, Cuicui Yang, Guanhua Song, Chengye Guo, Lin Wang, Hongsheng Yu
Oncotarget.2016; 7(15): 20041. CrossRef
Hepatocellular carcinoma and microRNA: New perspectives on therapeutics and diagnostics
Ningning Yang, Nsikak R. Ekanem, Clement A. Sakyi, Sidhartha D. Ray
Advanced Drug Delivery Reviews.2015; 81: 62. CrossRef
Reduced expression of microRNA-134 correlates with malignancy and poor prognosis in human glioma
Jianfeng Zhong, Bing Li
Journal of Clinical Neuroscience.2015; 22(3): 583. CrossRef
2015 update on the diagnosis and management of neoplastic pericardial disease
Chiara Lestuzzi, Massimiliano Berretta, Witold Tomkowski
Expert Review of Cardiovascular Therapy.2015; 13(4): 377. CrossRef
Extracellular microRNAs in bronchoalveolar lavage samples from patients with lung diseases as predictors for lung cancer
Grit Rehbein, Bernd Schmidt, Michael Fleischhacker
Clinica Chimica Acta.2015; 450: 78. CrossRef

16,023 View
136 Download
38 Web of Science
27 Crossref

Intrapleural Chemotherapy with Cisplatin and Cytarabine in the Management of Malignant Pleural Effusion: Kee Won Kim, Suk Young Park, Myung Sook Kim, Seok Chan Kim, Eun Hee Lee, So Young Shin, Jong Ho Lee, Jong Bum Kweon, Kuhn Park; Cancer Res Treat. 2004;36(1):68-71. Published online February 29, 2004; DOI: https://doi.org/10.4143/crt.2004.36.1.68

Abstract PDF PubReader ePub

Purpose

The purpose of this study was to evaluate the efficacy of intrapleural chemotherapy (IPC) with cisplatin and cytarabine in the management of malignant pleural effusion (MPE) from non-small-cell lung cancer (NSCLC).

Materials and Methods

A prospective analysis was carried out on 40 patients with pathologically proven MPE from NSCLC who had received IPC. A single dose of cisplatin 100 mg/m² plus cytarabine 1200 mg/m² in 250 ml normal saline was instilled into the pleural space via a chest tube and drained 4 hours later. Patients were evaluated for toxicities and responses at 1, 2, & 3 weeks and then at monthly intervals if possible. Systemic chemotherapy was administered, if the patient agreed to receive it, after achieving complete control (CC) of MPE.

Results

The median duration of chest tube insertion for drainage was 7 (3~32) days. Among the assessable 37 patients, CC and partial control (PC) were 32 (86.5%) and 4 (10.8%) patients, respectively (overall response rate 97.3%). The median duration of response was 12 months (2~23) and there were only two relapses of IPC after achieving CC. Among the 35 patients who were assessable until they died, 28 patients (80.0%) maintained CC until the last follow-up. There was only one toxic death and the toxicities of IPC, versus the results obtained, were deemed acceptable.

Conclusion

The procedures were tolerable to the patients and chemotherapy-induced complications were at an acceptable level. The outcome of this trial indicates that IPC has a superior and long lasting treatment response in the management of patients with MPE from NSCLC.

Citations

Citations to this article as recorded by

Efficacy of hyperthermic intrathoracic chemotherapy for initially diagnosed lung cancer with symptomatic malignant pleural effusion
Zihui Li, Jie Deng, Fei Yan, Li Liu, Yanling Ma, Jianhai Sun
Scientific Reports.2023;[Epub] CrossRef
Survival Benefits for Pulmonary Adenocarcinoma With Malignant Pleural Effusion After Thoracoscopic Surgical Treatment: A Real-World Study
Xin Li, Mingbiao Li, Jinshuang Lv, Jinghao Liu, Ming Dong, Chunqiu Xia, Honglin Zhao, Song Xu, Sen Wei, Zuoqing Song, Gang Chen, Hongyu Liu, Jun Chen
Frontiers in Oncology.2022;[Epub] CrossRef
Modified indwelling pleural catheter versus silver nitrate pleurodesis for the management of malignant pleural effusion
Mohammed F. Abdelghany, Khaled Essmat, Atef Farouk El-Karn, Sahar Farghly Youssif
The Egyptian Journal of Chest Diseases and Tuberculosis.2022; 71(2): 248. CrossRef
Chinese herbal injections versus intrapleural cisplatin for lung cancer patients with malignant pleural effusion: A Bayesian network meta-analysis of randomized controlled trials
Yi-Fang Xu, Yun-Ru Chen, Fan-Long Bu, Yu-Bei Huang, Yu-Xin Sun, Cheng-Yin Li, Jodi Sellick, Jian-Ping Liu, Dan-Mei Qin, Zhao-Lan Liu
Frontiers in Oncology.2022;[Epub] CrossRef
Making cold malignant pleural effusions hot: driving novel immunotherapies
Pranav Murthy, Chigozirim N. Ekeke, Kira L. Russell, Samuel C. Butler, Yue Wang, James D. Luketich, Adam C. Soloff, Rajeev Dhupar, Michael T. Lotze
OncoImmunology.2019; 8(4): e1554969. CrossRef
Efficacy and safety of intrapleural cisplatin versus silver nitrate in treatment of malignant pleural effusion
Mohammad K. El Badrawy, Raed El-Metwally Ali, Asem A. Hewidy, Mohamed A. El-Layeh, Fatma M. F. Akl, Abdelhadi Shebl
Egyptian Journal of Bronchology.2018; 12(1): 98. CrossRef
Biodegradable drug-eluting pellets provide steady and sustainable cisplatin release in the intrapleural cavity: In vivo and in vitro studies
Yin-Kai Chao, Yu-Wen Wen, Kuo-Sheng Liu, Yi-Chuan Wang, Chih-Wei Wang, Shih-Jung Liu
International Journal of Pharmaceutics.2015; 484(1-2): 38. CrossRef

9,009 View
58 Download
7 Crossref

Cytogenetic Study in Suspicious Cases of Malignant Pleural Effusion: Seung Bum Han, Dae Kwang Kim; Cancer Res Treat. 2002;34(3):234-238. Published online June 30, 2002; DOI: https://doi.org/10.4143/crt.2002.34.3.234

Abstract PDF

PURPOSE
This study was performed to detect malignant cells in suspicious cases of malignant pleural effusion by cytogenetic analysis. MATERIALS AND METGODS: Eleven cases with pleural effusion were included in this study. Cells in pleural effusion were treated by direct, or short term, culture to prepare chromosomes. To analyze chromosomes, the G-banding method was used.
RESULTS
Chromosome preparations succeeded in 10 cases. 5 cases had normal karyotypes, but in 2 of these cases malignant cells were detected on cytological examination. The other 5 cases had abnormal chromosomes, but on cytological examination showed normal cell appearances.
CONCLUSION
Cytogenetic analysis of pleural effusions is not used routinely, but is more sensitive than the cytological examination of malignant pleural effusions. So, chromosome analysis is a good diagnostic tool, when chromosomal abnormalities are detected in an effusion. If a combination of cytology and cytogenetic study are used, the chance of detecting malignant cells in pleural effusion will be higher, and then more invasive diagnostic procedures, such as thoracoscopy or thoracotomy, could be avoided.

Citations

Citations to this article as recorded by

Sensitivity and complications of thoracentesis and thoracoscopy: a meta-analysis
Gabriela Martinez-Zayas, Sofia Molina, David E. Ost
European Respiratory Review.2022; 31(166): 220053. CrossRef

3,851 View
26 Download
1 Crossref

Intrapleural Chemotherapy with Cisplatin and Cytarabine in the Manabement of Malignant Pleural Effusion: Suk Young Park, Baik Jong Seo; J Korean Cancer Assoc. 1996;28(4):698-705.

Abstract PDF: Malignant pleural effusion is a common snd signigicant problem in patients with advanced malignancies. The optimal means of control are not defined. Pleurodesis with tetracycline or other sclerosing agents has been the usual treatment for malignant pleural effusions. Intracavitary cisplatin-based chemotherapy has been recently reported to be successful in some clinical trials for the purpose of controlling malignant exudate and favored by some authors because it is thought to be cytotoxic rather than sclerosing, that is, the potential advantage of treating the underlying malignancy in addition to controlling the effusion. This study evaluated intrapleural cisplatin and cytarabine combination chemotherapy in 15 patients with malignant pleural effusions from lung and other cancers. A single dose of cisplatin plus cytarabine was instilled into pleural space via a chest tube and drained 4 hours later. Systemic chemotheapy and/or radiation therapy were given at least 3 weeks apart after intrapleural chemotherapy if decided to recieve them. The outcome of this trial indicated that the intrapleural chemotherapy had high and durable treatment response(87%; CR 13 cases(81%)) and the median duration of response was 29 weeks which seemed long enough to be little maiignant pieural effusion in 7 cases among 9 patients followed up till moribund state. The procedures were tolerable in all the cases and chemothrapy induced complications were not significant.

2,730 View
20 Download

Fibrinolytic Profiles in Malignant Pleural Effusion: Seung Ho Baik, Jin Woo Jeon, Jong Ho Won, Dae Sik Hong, Hee Sook Park; J Korean Cancer Assoc. 1996;28(4):705-710.

Abstract PDF: Plasminogen activators(PAs) and their inhibitors, plasminogen activator inhibitor-l(PAI-l) are known to play an important role in tumor invasion and metastasis. The differentiation of malignant pleural effusion(PE) from non-malignant pleural effusion is important for the management of a patient. Since malignant PE is a form of metastasis, and malignant cells are considered to be able to produce PAs or PAI-1, it seems reasonable to assume that PAa and PAI-1 in PE will be in somewhat different from that in non-malignant PE. We examined urokinase- type plasminogeo activator(uPA) and uPA receptor(uPAR) and tissue-type plasminogen activator(tPA), PAI-1 antigen using ELISA method and conventional laboratory tests and adenosine deaminase(ADA) in PEs. Levels of uPA, uPAR, tPA and PAI-1 were significantly increased in malignant and tuberculous PE than transudates(p<0.05) but not statistically significant between malignant and tuberculous PE. ADA in PE showed significantly increased in tuberculous PE than malignant PE and transudate(p<0.05). These data suggests that measurement of uPA, uPAR, tPA, PAI-1 antigen in addition to ADA could be helpful to differentiate malignant PE from tuberculous PE and transudate.

2,559 View
15 Download

First
Prev
Page of 1
Next
Last

Search